文献速递骨肿瘤小儿骨科

我们能否准确预测接受肉瘤治疗的儿科患者的成年身高?

Can We Accurately Predict Adult Height in Pediatric Patients Who Undergo Treatment for Sarcoma?
PubMed 文献 · Clin Orthop Relat Res · 2025-02-06

该回顾性先导研究纳入56例在骨骼成熟前完成化疗并存活至成熟的儿童肉瘤患者,发现Paley乘法法在女性和男性中分别平均高估成年身高4.3±5.9 cm和4.9±6.1 cm,且CDC z评分在成熟时低于诊断时;作者基于性别、首次化疗年龄和诊断时身高建立的新预测模型比Paley法更接近实际身高,但需更大规模研究验证。

要点

  • Paley法在女性中平均高估成年身高4.3±5.9 cm(95%CI 1.8-6.8,p<0.001),男性中高估4.9±6.1 cm(95%CI 2.6-7.1,p<0.001)。
  • 成熟时CDC z评分中位数0.47(范围-1.7至3.2)低于诊断时0.73(范围-1.7至2.6),中位差-0.26(p<0.001)。
  • 作者新模型纳入性别、首次化疗年龄和诊断时身高,预测值最接近实际身高,但需更大规模多样队列研究验证。

核心结论

  • 作者认为新身高预测模型比Paley法和CDC z评分更准确地考虑了儿童肉瘤治疗对生长的限制。
  • 作者认为该模型有助于外科医生规划生长中儿童下肢肿瘤的复杂手术重建,并把握成年身高及肢体不等长风险。
  • 作者指出需更大规模、更多样化队列的研究来识别可能影响模型准确性的因素。

研究设计与样本

  • 回顾性先导研究,来自单一儿童肉瘤中心1976年至2022年6月期间以诊断代码识别的223例儿童肉瘤患者。
  • 纳入标准为骨骼成熟前完成化疗、存活至成熟且身高数据完整,最终56例符合纳入标准,167例被排除。
  • 排除原因包括未接受化疗9%(15/167)、骨骼成熟后接受化疗20%(33/167)、未存活至骨骼成熟19%(31/167)、病历审查时未达骨骼成熟43%(72/167)、治疗数据不足7%(11/167)和失访3%(5/167)。
  • 新模型通过多元回归使用三分之二队列推导,剩余三分之一用于测试准确性。

主要发现

  • 纳入患者中女性43%(24/56),男性57%(32/56);原发骨肿瘤70%(39/56),其中下肢受累64%(25/39)。
  • 骨肉瘤41%(23/56)和尤文肉瘤36%(20/56)为主;多柔比星82%(46/56)和环磷酰胺61%(34/56)为最常见化疗药,平均治疗时长76±88周。
  • 女性诊断平均年龄11±4岁,骨骼成熟16±1岁;男性诊断平均年龄14±3岁,骨骼成熟17±1岁。
  • Paley法在女性中平均高估成年身高4.3±5.9 cm(95%CI 1.8-6.8,p<0.001),男性中高估4.9±6.1 cm(95%CI 2.6-7.1,p<0.001)。
  • 成熟时CDC z评分中位数0.47(范围-1.7至3.2)低于诊断时0.73(范围-1.7至2.6),中位差-0.26(p<0.001);诊断年龄越小,z评分和预测身高差异越大。

关键数值与推荐

  • 新身高预测模型方程(结果以厘米计):116 + 12(若男性)+ 0.6 ×(诊断时身高cm)- 3.2 ×(首次化疗年龄岁)。

临床怎么用

  • 作者认为新模型使外科医生能更好地规划生长中儿童下肢肿瘤的复杂手术重建,因为能更好地把握最终成年身高及相关的肢体不等长风险。

局限性

  • 原文指出需更大规模、更多样化队列的研究来识别可能影响模型准确性的因素。
  • 证据等级为IV级,治疗性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcoma and its treatment has the potential to limit adult height attainment in skeletally immature patients. However, evidence on the extent of this limitation in sarcoma specifically is mixed, and existing height prediction tools such as the Paley multiplier method have proven unreliable in this setting. As such, orthopaedic surgeons are left with the challenge of counseling patients and their families on expected height deficits without an adequate understanding of the extent of these deficits. Equally important, these surgeons must also understand the amount of skeletal growth remaining during the presurgical planning process for limb reconstruction to adequately grasp a patient's risk of subsequent limb length discrepancy. QUESTIONS/PURPOSES: (1) To what extent does pediatric sarcoma and its treatment limit adult height attainment? (2) Using retrospective data on pediatric patients with sarcoma, can we create a height prediction model that yields more accurate estimates of expected adult height than the Paley multiplier method? METHODS: For this retrospective pilot study, 223 pediatric patients with sarcoma from a single pediatric sarcoma center between 1976 and June 2022 were identified using diagnostic codes. Inclusion criteria were completion of chemotherapy before skeletal maturity, survival to maturity, and complete height data (that is, height at diagnosis and at skeletal maturity). Of the 223 patients identified as potentially eligible, 56 met inclusion criteria. The remaining 167 patients were excluded on the basis of not receiving chemotherapy (9% [15 of 167]), receiving chemotherapy after skeletal maturity was reached (20% [33 of 167]), not surviving to skeletal maturity (19% [31 of 167]), not reaching skeletal maturity at the time of chart review (43% [72 of 167]), having insufficient treatment data available for analysis (7% [11 of 167]), or being lost to follow-up (that is, no further clinic visits where height at skeletal maturity was recorded) (3% [5 of 167]). Data collection encompassed cancer type; age, height, and weight at diagnosis and maturity; and treatment characteristics. A total of 43% (24 of 56) were female and 57% (32 of 56) were male. Among included patients, 70% (39 of 56) had primary bone tumors, of which 64% (25 of 39) involved lower extremity. Diagnoses of osteosarcoma (41% [23 of 56]) and Ewing sarcoma (36% [20 of 56]) predominated. Doxorubicin (82% [46 of 56]) and cyclophosphamide (61% [34 of 56]) were the most common chemotherapeutics; the mean ± SD treatment duration was 76 ± 88 weeks. Female patients were diagnosed at a mean age of 11 ± 4 years, reaching skeletal maturity at 16 ± 1 years. Male patients were diagnosed at a mean age of 14 ± 3 years, reaching skeletal maturity at 17 ± 1 years. We compared CDC z-scores, which quantify patient height relative to the population mean using SD and percentiles, at diagnosis and maturity to track growth before and after sarcoma treatment, thus quantifying our cohort's growth trajectories relative to the population mean. The Paley multiplier method is a quick and easy-to-use limb length prediction tool that utilizes validated age- and sex-specific multipliers. Its predictions based on height at diagnosis were compared with final attained heights. A novel height prediction model accounting for chemotherapy was derived via multiple regression using two-thirds of the cohort. The remaining one-third was used to test accuracy of the model. RESULTS: Skeletally immature patients diagnosed with and treated for sarcoma were found to achieve shorter heights at maturity than predicted by the Paley method and CDC growth curves. The Paley method overpredicted adult height by a mean ± SD of 4.3 ± 5.9 cm in female patients (95% confidence interval 1.8 to 6.8; p < 0.001) and 4.9 ± 6.1 cm in male patients (95% CI 2.6 to 7.1; p < 0.001). Median (range) CDC z-scores at maturity (0.47 [-1.7 to 3.2]) were lower than at diagnosis (0.73 [-1.7 to 2.6]) (median difference -0.26; p < 0.001). Patients diagnosed at younger ages were more likely to have larger discrepancies in both CDC z-scores at maturity and in predicted heights. Our novel height prediction model yielded predictions most similar to actual heights attained by incorporating sex, age at first chemotherapy, and height at diagnosis into the following equation (result given in centimeters): 116 + 12 (if male) + 0.6 × (height at diagnosis in cm) - 3.2 × (age at first chemotherapy in years). CONCLUSION: Our novel height prediction model more accurately accounts for growth limitations imposed by pediatric sarcoma treatment compared with the Paley method and CDC z-scores. With our model, surgeons are now better equipped to plan complex surgical reconstruction of lower extremity tumors in growing children because of a better grasp of eventual adult height and, relatedly, risk for limb length discrepancies. However, to identify any factors that may influence the model's accuracy, larger studies with more diverse cohorts are needed.Level of Evidence Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Prigmore B, Lindsay SE, Agloro A, et al. Can We Accurately Predict Adult Height in Pediatric Patients Who Undergo Treatment for Sarcoma? Clin Orthop Relat Res. 2025. PMID: 39915098. doi:10.1097/CORR.0000000000003409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。